FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
This article was originally published in The Tan Sheet
Executive Summary
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
You may also be interested in...
J&J Woes, Pharma Switch Outlook Lead "The Tan Sheet" 2010 Topics
Quality control problems for Johnson & Johnson's McNeil Consumer Healthcare business and the regulatory and congressional scrutiny that followed dominated the attention of drug and dietary supplement industry stakeholders in 2010.
J&J Delivers No Evidence FDA Knew Of "Phantom" Recall - Congressional Staff
Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff
FDA Warns In Recall Guidance Agency Has Arsenal Of Enforcement Options
FDA warns that even though it cannot mandate a drug recall, "it can take more authoritative legal actions" against firms selling defective health products